Войти в систему

Home
    - Создать дневник
    - Написать в дневник
       - Подробный режим

LJ.Rossia.org
    - Новости сайта
    - Общие настройки
    - Sitemap
    - Оплата
    - ljr-fif

Редактировать...
    - Настройки
    - Список друзей
    - Дневник
    - Картинки
    - Пароль
    - Вид дневника

Сообщества

Настроить S2

Помощь
    - Забыли пароль?
    - FAQ
    - Тех. поддержка



Пишет bioRxiv Subject Collection: Neuroscience ([info]syn_bx_neuro)
@ 2025-06-13 18:47:00


Previous Entry  Add to memories!  Tell a Friend!  Next Entry
Boolean Network Modeling Identifies Cognitive Resilience in the First Murine Model of Asymptomatic Alzheimer Disease
Alzheimer disease (AD) is a progressive neurodegenerative disorder defined by amyloid beta plaques and neurofibrillary tangles (NFTs), yet approximately 30% of aged individuals exhibit these hallmark lesions without developing cognitive impairment, a clinically silent condition termed asymptomatic AD (AsymAD). The molecular basis of this cognitive resilience remains poorly understood due to a lack of mechanistic models. Here, we integrate systems level Boolean network modeling with in vivo validation to define the transcriptomic logic of AsymAD and uncover a novel preclinical model. Using Boolean implication networks trained on large-scale human cortical RNA seq datasets, we identified a robust and invariant AD gene signature that accurately stratifies disease states across independent datasets. Application of this signature to Chromogranin A deficient PS19 mice (CgA-KO/PS19) revealed a unique resilience phenotype: male mice developed AD like molecular and neuropathological profiles in the pre-frontal cortex yet retained intact learning and memory. Female CgA-KO/PS19 mice displayed even greater protection, including reduced Tau phosphorylation and preserved synaptic ultrastructure. These findings establish the first validated murine model of AsymAD and identify CgA as a modifiable node linking neuroendocrine signaling, Tauopathy, and cognitive preservation. This work provides a scalable platform to probe sex-specific resilience, uncover early-stage biomarkers, and accelerate preventive therapeutic development in AD.


(Читать комментарии) (Добавить комментарий)